Drugs in clinical development for multiple sclerosis: focusing on anti-CD20 antibodies

Author： Gasperini Claudio Haggiag Shalom Ruggieri Serena

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.22, Iss.10, 2013-10, pp. : 1243-1253

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Antibodies against CD20 (rituximab) for treating multiple sclerosis: US20100233121

By Taupin Philippe

Expert Opinion on Therapeutic Patents, Vol. 21, Iss. 1, 2011-01 ,pp. : 111-114

Informa Healthcare

Access to resources Recommend Favorite

Drugs in Clinical Development for Multiple Sclerosis: Summary and Table

Pharmaceutical Medicine, Vol. 26, Iss. 2, 2012-04 ,pp. : 103-112

Adis International

Access to resources Recommend Favorite

Development of a new fully human anti-CD20 monoclonal antibody for the treatment of B-cell malignancies

By Bornstein Gadi Quéva Christophe Tabrizi Mohammad Abbema Anne Chavez Carlos Wang Ping Foord Orit Ahluwalia Kiran Laing Naomi Raja Sandhya Wen Shenghua Green Larry Yang Xiaodong Webster Carl Stewart Ross Blakey David

Investigational New Drugs, Vol. 28, Iss. 5, 2010-10 ,pp. : 561-574

Springer Publishing Company

Access to resources Recommend Favorite

Development of Anti-CD20 Antigen-Targeting Therapies for B-cell Lymphoproliferative Malignancies - The State of the Art

Current Drug Targets, Vol. 17, Iss. 9, 2016-07 ,pp. : 1072-1082

Bentham Science Publishers

Access to resources Recommend Favorite

Antibodies as therapeutics for multiple sclerosis

PHARMAKON, Vol. 2, Iss. 6, 2014-11 ,pp. : 403-413

Govi-Verlag

Access to resources Recommend Favorite